세포막 투과 펩티드 시장 규모, 점유율, 동향 분석 리포트 : 유형별, 용도별, 최종 용도별, 지역별, 부문별 예측(2024-2030년)

Cell Penetrating Peptide Market Growth & Trends:

The global cell penetrating peptide market size is expected to reach USD 2.85 billion by 2030, expandingat a CAGR of 10.08% from 2024 to 2030, according to a new report by Grand View Research, Inc. Growing demand for targeted drug delivery methods is the primary factor propelling the growth. Technological advancements in chemical modification strategies & peptide synthesis techniques and increasing R&D activities to introduce precise therapeutics are increasing the demand for cell penetrating peptides in the market.

Moreover, rising approvals of novel drugs based on CPP technology is expected to offer lucrative opportunities for the key players during the study period. For instance, in September 2022, Revance Therapeutics, Inc. received U.S. Food and Drug Administration approval for DAXXIFY, which is developed based on cell-penetrating technology for temporary improvement of severe to moderate frown lines. This approval is projected to boost the market growth.

Advancements in the production processes of peptides are expected to drive the market. Manufacturers and suppliers are focused on developing new methods for synthesizing peptides, such as cell penetrating peptides. Improvement and automation of the purification process and lower waste generation are further increasing the demand for CPPs in different applications. For instance, in March 2022, Creative Peptides introduced innovative peptide drug discovery services to speed the development of peptide therapeutics, including CPPs therapies.

Growing funding for developing novel drugs to treat numerous diseases using cell penetrating peptides is anticipated to open new avenues for the market stakeholders. For instance, in September 2022, the Keck Graduate Institute received a research grant of USD 500,000 from the Foundation for Angelman Syndrome Therapeutics for two years to support research activities related to CPPs to targetAngelman Syndrome. Such initiatives are boosting the cell penetrating peptide sector growth.

However, cell penetrating peptides can certainly be synthesized on solid support using manual methods, and these can be tedious and time-intensive. The equipment for new systems can cost from USD 30,000 to USD 200,000 and above, depending on the synthesis scale capability & software. Hence, the high cost of manufacturing equipment may hamper the development of cell penetrating peptides by small players and emerging economies. On the other hand, continuous technological advancements are likely to boost the applications of CPPs during the forecast period.

Cell Penetrating Peptide Market Report Highlights:

• Based on type, the synthetic CPPs segment dominated the market in 2023 owing to their intrinsic property of delivering therapeutic molecules such as drugs, imaging agents, and nucleic acids
• Based on application, the drug delivery segment held the largest segment share of the market in 2023, attributable to their low toxicity and efficiency of drug delivery into target cells
• Based on end-use, the pharmaceutical & biotechnology companies segment led the market in 2023. It can be attributed to the rising utilization of peptides in pharmaceutical and biotechnology companies for R&D activities and the production of novel diagnostics and therapeutics
• North America has established a strong regional position with a highest market share owing to the increasing funding for cell penetrating peptide research, favorable government policies, technological advancements, and the presence of key operating players in the region

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation
  • 1.1.1. Market Definitions
• 1.2. Objectives
  • 1.2.1. Objective - 1
  • 1.2.2. Objective - 2
  • 1.2.3. Objective - 3
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information Or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity Flow Analysis
• 1.8. List Of Secondary Sources
• 1.9. List Of Abbreviations
• 1.10. List Of Primary Sources

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Type, Application, and End-use Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Segmentation and Scope
• 3.2. Market Lineage Outlook
  • 3.2.1. Parent Market Outlook
  • 3.2.2. Related/Ancillary Market Outlook
• 3.3. Market Dynamics
• 3.4. Market Drivers
  • 3.4.1. Technological Advancements of Peptide Synthesis
  • 3.4.2. Growing Demand for Targeted Drug Delivery
  • 3.4.3. Presence of Strong Pipeline
• 3.5. Market Restraint Analysis
  • 3.5.1. Increasing Complexity of Peptides
  • 3.5.2. High Cost of Manufacturing Equipment
• 3.6. Business Environment Analysis
  • 3.6.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
  • 3.6.2. Porter's Five Forces Analysis
  • 3.6.3. COVID-19 Impact Analysis

Chapter 4. Type Business Analysis

• 4.1. Cell Penetrating Peptide market: Type Movement Analysis
• 4.2. Protein Derived CPPs
  • 4.2.1. Protein Derived CPPs Market, 2018 - 2030 (USD Million)
• 4.3. Synthetic CPPs
  • 4.3.1. Synthetic CPPs Market, 2018 - 2030 (USD Million)
• 4.4. Chimeric CPPs
  • 4.4.1. Chimeric CPPs Market, 2018 - 2030 (USD Million)

Chapter 5. Application Business Analysis

• 5.1. Cell Penetrating Peptide Market: Application Movement Analysis
• 5.2. Drug Delivery
  • 5.2.1. Drug Delivery Market, 2018 - 2030 (USD Million)
• 5.3. Gene Delivery
  • 5.3.1. Gene Delivery Market, 2018 - 2030 (USD Million)
• 5.4. Diagnostics
  • 5.4.1. Diagnostics Market, 2018 - 2030 (USD Million)
• 5.5. Molecular Imaging
  • 5.5.1. Molecular Imaging Market, 2018 - 2030 (USD Million)
• 5.6. Others
  • 5.6.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. End-use Business Analysis

• 6.1. Cell Penetrating Peptide Market: End-use Movement Analysis
• 6.2. Pharmaceutical and Biotechnology Company
  • 6.2.1. Pharmaceutical and Biotechnology Companies Market, 2018 - 2030 (USD Million)
• 6.3. Contract Research Organizations (CROs)
  • 6.3.1. Contract Research Organizations (CROs) Market, 2018 - 2030 (USD Million)
• 6.4. Hospitals and Clinics
  • 6.4.1. Hospitals and Clinics Market, 2018 - 2030 (USD Million)
• 6.5. Others
  • 6.5.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. Regional Business Analysis

• 7.1. Cell Penetrating Peptide Market Share By Region, 2023 & 2030
• 7.2. North America
  • 7.2.1. North America Cell Penetrating Peptide market, 2018 - 2030 (USD Million)
  • 7.2.2. U.S.
    • 7.2.2.1. Key Country Dynamics
    • 7.2.2.2. Target Disease Prevalence
    • 7.2.2.3. Competitive Scenario
    • 7.2.2.4. Regulatory Framework
    • 7.2.2.5. Reimbursement Scenario
    • 7.2.2.6. U.S. Cell Penetrating Peptide market, 2018 - 2030 (USD MILLION)
  • 7.2.3. Canada
    • 7.2.3.1. Key Country Dynamics
    • 7.2.3.2. Target Disease Prevalence
    • 7.2.3.3. Competitive Scenario
    • 7.2.3.4. Regulatory Framework
    • 7.2.3.5. Reimbursement Scenario
    • 7.2.3.6. Canada Cell Penetrating Peptide market, 2018 - 2030 (USD Million)
• 7.3. Europe
  • 7.3.1. Europe Cell Penetrating Peptide market, 2018 - 2030 (USD Million)
  • 7.3.2. Germany
    • 7.3.2.1. Key Country Dynamics
    • 7.3.2.2. Target Disease Prevalence
    • 7.3.2.3. Competitive Scenario
    • 7.3.2.4. Regulatory Framework
    • 7.3.2.5. Reimbursement Scenario
    • 7.3.2.6. Germany Cell Penetrating Peptide market, 2018 - 2030 (USD Million)
  • 7.3.3. UK
    • 7.3.3.1. Key Country Dynamics
    • 7.3.3.2. Target Disease Prevalence
    • 7.3.3.3. Competitive Scenario
    • 7.3.3.4. Regulatory Framework
    • 7.3.3.5. Reimbursement Scenario
    • 7.3.3.6. UK Cell Penetrating Peptide market, 2018 - 2030 (USD Million)
  • 7.3.4. France
    • 7.3.4.1. Key Country Dynamics
    • 7.3.4.2. Target Disease Prevalence
    • 7.3.4.3. Competitive Scenario
    • 7.3.4.4. Regulatory Framework
    • 7.3.4.5. Reimbursement Scenario
    • 7.3.4.6. France Cell Penetrating Peptide market, 2018 - 2030 (USD Million)
  • 7.3.5. Italy
    • 7.3.5.1. Key Country Dynamics
    • 7.3.5.2. Target Disease Prevalence
    • 7.3.5.3. Competitive Scenario
    • 7.3.5.4. Regulatory Framework
    • 7.3.5.5. Reimbursement Scenario
    • 7.3.5.6. Italy Cell Penetrating Peptide market, 2018 - 2030 (USD Million)
  • 7.3.6. Spain
    • 7.3.6.1. Key Country Dynamics
    • 7.3.6.2. Target Disease Prevalence
    • 7.3.6.3. Competitive Scenario
    • 7.3.6.4. Regulatory Framework
    • 7.3.6.5. Reimbursement Scenario
    • 7.3.6.6. Spain Cell Penetrating Peptide market, 2018 - 2030 (USD Million)
  • 7.3.7. Denmark
    • 7.3.7.1. Key Country Dynamics
    • 7.3.7.2. Target Disease Prevalence
    • 7.3.7.3. Competitive Scenario
    • 7.3.7.4. Regulatory Framework
    • 7.3.7.5. Reimbursement Scenario
    • 7.3.7.6. Denmark Cell Penetrating Peptide market, 2018 - 2030 (USD Million)
  • 7.3.8. Sweden
    • 7.3.8.1. Key Country Dynamics
    • 7.3.8.2. Target Disease Prevalence
    • 7.3.8.3. Competitive Scenario
    • 7.3.8.4. Regulatory Framework
    • 7.3.8.5. Reimbursement Scenario
    • 7.3.8.6. Sweden Cell Penetrating Peptide market, 2018 - 2030 (USD Million)
  • 7.3.9. Norway
    • 7.3.9.1. Key Country Dynamics
    • 7.3.9.2. Target Disease Prevalence
    • 7.3.9.3. Competitive Scenario
    • 7.3.9.4. Regulatory Framework
    • 7.3.9.5. Reimbursement Scenario
    • 7.3.9.6. Norway Cell Penetrating Peptide market, 2018 - 2030 (USD Million)
• 7.4. Asia Pacific
  • 7.4.1. Asia Pacific Cell Penetrating Peptide market, 2018 - 2030 (USD Million)
  • 7.4.2. Japan
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Target Disease Prevalence
    • 7.4.2.3. Competitive Scenario
    • 7.4.2.4. Regulatory Framework
    • 7.4.2.5. Reimbursement Scenario
    • 7.4.2.6. Japan Cell Penetrating Peptide market, 2018 - 2030 (USD Million)
  • 7.4.3. China
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Target Disease Prevalence
    • 7.4.3.3. Competitive Scenario
    • 7.4.3.4. Regulatory Framework
    • 7.4.3.5. Reimbursement Scenario
    • 7.4.3.6. China Cell Penetrating Peptide market, 2018 - 2030 (USD Million)
  • 7.4.4. India
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Target Disease Prevalence
    • 7.4.4.3. Competitive Scenario
    • 7.4.4.4. Regulatory Framework
    • 7.4.4.5. Reimbursement Scenario
    • 7.4.4.6. India Cell Penetrating Peptide market, 2018 - 2030 (USD Million)
  • 7.4.5. South Korea
    • 7.4.5.1. Key Country Dynamics
    • 7.4.5.2. Target Disease Prevalence
    • 7.4.5.3. Competitive Scenario
    • 7.4.5.4. Regulatory Framework
    • 7.4.5.5. Reimbursement Scenario
    • 7.4.5.6. South Korea Cell Penetrating Peptide market, 2018 - 2030 (USD Million)
  • 7.4.6. Australia
    • 7.4.6.1. Key Country Dynamics
    • 7.4.6.2. Target Disease Prevalence
    • 7.4.6.3. Competitive Scenario
    • 7.4.6.4. Regulatory Framework
    • 7.4.6.5. Reimbursement Scenario
    • 7.4.6.6. Australia Cell Penetrating Peptide market, 2018 - 2030 (USD Million)
  • 7.4.7. Thailand
    • 7.4.7.1. Key Country Dynamics
    • 7.4.7.2. Target Disease Prevalence
    • 7.4.7.3. Competitive Scenario
    • 7.4.7.4. Regulatory Framework
    • 7.4.7.5. Reimbursement Scenario
    • 7.4.7.6. Thailand Cell Penetrating Peptide market, 2018 - 2030 (USD Million)
• 7.5. Latin America
  • 7.5.1. Latin America Cell Penetrating Peptide market, 2018 - 2030 (USD Million)
  • 7.5.2. Brazil
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Target Disease Prevalence
    • 7.5.2.3. Competitive Scenario
    • 7.5.2.4. Regulatory Framework
    • 7.5.2.5. Reimbursement Scenario
    • 7.5.2.6. Brazil Cell Penetrating Peptide market, 2018 - 2030 (USD Million)
  • 7.5.3. Mexico
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Target Disease Prevalence
    • 7.5.3.3. Competitive Scenario
    • 7.5.3.4. Regulatory Framework
    • 7.5.3.5. Reimbursement Scenario
    • 7.5.3.6. Mexico Cell Penetrating Peptide market, 2018 - 2030 (USD Million)
  • 7.5.4. Argentina
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Target Disease Prevalence
    • 7.5.4.3. Competitive Scenario
    • 7.5.4.4. Regulatory Framework
    • 7.5.4.5. Reimbursement Scenario
    • 7.5.4.6. Argentina Cell Penetrating Peptide market, 2018 - 2030 (USD Million)
• 7.6. MEA
  • 7.6.1. MEA Cell Penetrating Peptide market, 2018 - 2030 (USD Million)
  • 7.6.2. South Africa
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Target Disease Prevalence
    • 7.6.2.3. Competitive Scenario
    • 7.6.2.4. Regulatory Framework
    • 7.6.2.5. Reimbursement Scenario
    • 7.6.2.6. South Africa Cell Penetrating Peptide market, 2018 - 2030 (USD Million)
  • 7.6.3. Saudi Arabia
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Target Disease Prevalence
    • 7.6.3.3. Competitive Scenario
    • 7.6.3.4. Regulatory Framework
    • 7.6.3.5. Reimbursement Scenario
    • 7.6.3.6. Saudi Arabia Cell Penetrating Peptide market, 2018 - 2030 (USD Million)
  • 7.6.4. UAE
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Target Disease Prevalence
    • 7.6.4.3. Competitive Scenario
    • 7.6.4.4. Regulatory Framework
    • 7.6.4.5. Reimbursement Scenario
    • 7.6.4.6. UAE Cell Penetrating Peptide market, 2018 - 2030 (USD Million)
  • 7.6.5. Kuwait
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Target Disease Prevalence
    • 7.6.5.3. Competitive Scenario
    • 7.6.5.4. Regulatory Framework
    • 7.6.5.5. Reimbursement Scenario
    • 7.6.5.6. Kuwait Cell Penetrating Peptide market, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Participant's overview
• 8.2. Financial performance
• 8.3. Participant categorization
  • 8.3.1. Market Leaders
  • 8.3.2. Cell Penetrating Peptide market Share Analysis, 2023
  • 8.3.3. Company Profiles
    • 8.3.3.1. Pepscan
    • 8.3.3.1.1. Company Overview
    • 8.3.3.1.2. Financial Performance
    • 8.3.3.1.3. Product Benchmarking
    • 8.3.3.1.4. Strategic Initiatives
    • 8.3.3.2. Creative Peptides
    • 8.3.3.2.1. Company Overview
    • 8.3.3.2.2. Financial Performance
    • 8.3.3.2.3. Product Benchmarking
    • 8.3.3.2.4. Strategic Initiatives
    • 8.3.3.3. Cupidpeptides
    • 8.3.3.3.1. Company Overview
    • 8.3.3.3.2. Financial Performance
    • 8.3.3.3.3. Product Benchmarking
    • 8.3.3.3.4. Strategic Initiatives
    • 8.3.3.4. AltaBioscience Ltd
    • 8.3.3.4.1. Company Overview
    • 8.3.3.4.2. Financial Performance
    • 8.3.3.4.3. Product Benchmarking
    • 8.3.3.4.4. Strategic Initiatives
    • 8.3.3.5. AnaSpec
    • 8.3.3.5.1. Company Overview
    • 8.3.3.5.2. Financial Performance
    • 8.3.3.5.3. Product Benchmarking
    • 8.3.3.5.4. Strategic Initiatives
    • 8.3.3.6. Peptomyc
    • 8.3.3.6.1. Company Overview
    • 8.3.3.6.2. Financial Performance
    • 8.3.3.6.3. Product Benchmarking
    • 8.3.3.6.4. Strategic Initiatives
    • 8.3.3.7. BioAlps
    • 8.3.3.7.1. Company Overview
    • 8.3.3.7.2. Financial Performance
    • 8.3.3.7.3. Product Benchmarking
    • 8.3.3.7.4. Strategic Initiatives
    • 8.3.3.8. Sarepta Therapeutics, Inc.
    • 8.3.3.8.1. Company Overview
    • 8.3.3.8.2. Financial Performance
    • 8.3.3.8.3. Product Benchmarking
    • 8.3.3.8.4. Strategic Initiatives
    • 8.3.3.9. REVANCE THERAPEUTICS
    • 8.3.3.9.1. Company Overview
    • 8.3.3.9.2. Financial Performance
    • 8.3.3.9.3. Product Benchmarking
    • 8.3.3.9.4. Strategic Initiatives
    • 8.3.3.10. Polypeptide Group
    • 8.3.3.10.1. Company Overview
    • 8.3.3.10.2. Financial Performance
    • 8.3.3.10.3. Product Benchmarking
    • 8.3.3.10.4. Strategic Initiatives
    • 8.3.3.11. Bachem
    • 8.3.3.11.1. Company Overview
    • 8.3.3.11.2. Financial Performance
    • 8.3.3.11.3. Product Benchmarking
    • 8.3.3.11.4. Strategic Initiatives
  • 8.3.4. Strategy Mapping
    • 8.3.4.1. Expansion
    • 8.3.4.2. Acquisition
    • 8.3.4.3. Collaborations
    • 8.3.4.4. Disease Type/Drug Class Launch
    • 8.3.4.5. Partnerships
    • 8.3.4.6. Others